We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Polysome Screen Identifies Cancer Related MicroRNAs

By LabMedica International staff writers
Posted on 04 Sep 2018
An international research team has developed a polysome-based method for detecting microRNAs (miRNAs) that act to promote or sustain growth of malignant mesothelioma and other types of cancer.

MicroRNAs are short RNA molecules about 22 nucleotides in length. More...
Essentially, miRNAs specifically target certain messenger RNAs (mRNAs) to prevent them from coding for a specific protein. The expression of miRNAs in cancer has been widely studied and has allowed this activity to be classified as oncomir (also oncomiR) or oncosuppressor.

The dysregulation of oncomirs has been associated with specific cancer forming events such as malignant transformation and metastasis. Some oncomir genes are oncogenes, in that overexpression of the gene leads to cancerous growth. Other oncomir genes are tumor suppressors in a normal cell, so that under expression of the gene leads to cancerous growth.

In order to identify biologically active oncomirs, investigators at the National Institute of Molecular Genetics (Milan, Italy) and their collaborators in Italy and the United States developed a screen for miRNAs acting on the polysomes of malignant mesothelioma (MPM) cells. A polysome (or polyribosome) is a complex comprising an mRNA molecule and two or more ribosomes that act to translate mRNA instructions into polypeptides.

They investigators reported in the August 2, 2018, online edition of the journal Cancer Research that only a small percentage of expressed miRNAs physically associated with polysomes. On polysomes, they identified miRNAs already characterized in MPM, as well as novel ones like miR-24-3p, which acted as a pro-migratory miRNA in all cancer cells tested. They found that miR-24-3p positively regulated the activity of the enzyme Rho-GTP, a kinase involved in regulating the shape and movement of cells by acting on the cytoskeleton. In contrast, inhibition of miR-24-3p reduced growth in MPM cells.

Among the specific targets of miR-24-3p was cingulin, a tight junction protein that inhibited Rho-GTP activity. Overexpression of miR-24-3p was found to only partially inhibit cingulin mRNA but to completely eliminate cingulin protein, confirming its action via translational repression. This finding confirmed that miR-24-3p was an oncomir, and suggested that identification of polysome-associated miRNAs efficiently sorted out biologically active miRNAs from inactive ones.

“We have identified a novel approach for identifying relevant miRNA in cancer biology,” said senior author Dr. Stefano Biffo, professor of cell biology at the University of Milan (Italy) and group leader at the National Institute of Molecular Genetics. “By examining the polyribosomes where translation occurs, this "focused" search has allowed us to identify that miR-24-3p (a particular miRna) expression is relevant to cancer progression and metastasis.”

Related Links:
National Institute of Molecular Genetics
University of Milan


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.